Oppie, note the "in years" bit.... it will not get there overnight.... but this was a huge announcement.
Also, there is a massive upside number to this. From the announcement.
We expect that marketing OvPlex on such a large scale will be the catalyst that will see HealthLinx target other countries and launch what we feel is a superior diagnostic for ovarian cancer to any other product available. In line with our annual report we have opened discussions in Korea, China, other European countries and we have been approached by some Central South American countries. These present strong commercial opportunities.
HTX Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
